Current Infectious Disease Reports

, Volume 5, Issue 6, pp 513–520 | Cite as

Cardiovascular complications in patients with HIV infection

  • Karolina M. Zareba
  • Steven E. Lipshultz
Article

Abstract

As advances in early diagnosis and aggressive therapy, as well as better supportive care, become available to a larger number of patients with HIV infection, survival is being prolonged, and more patients are experiencing cardiac abnormalities. The most common cardiac manifestations of HIV disease are dilated cardiomyopathy, myocarditis, pericardial effusion, endocarditis, pulmonary hypertension, HIV-associated malignant neoplasms, and drug-related cardiotoxicity. The introduction of highly active antiretroviral therapy (HAART) regimens has substantially modified the course of HIV disease by lengthening survival and improving quality of life of HIV-infected patients. However, early data have raised concerns about HAART being associated with an increase in peripheral and coronary arterial disease. This review discusses the principal HIV-associated cardiovascular manifestations and emphasizes new knowledge about their prevalence, pathogenesis, and treatment.

Keywords

Pulmonary Hypertension Heart Rate Variability Endocarditis Dilate Cardiomyopathy Pericardial Effusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    AIDS Epidemic Update December 2002. http://www.unaids.org. Accessed February 12, 2003.Google Scholar
  2. 2.
    Bozzette SA, Ake CF, Tam HK, et al.: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702–710.PubMedCrossRefGoogle Scholar
  3. 3.
    Lipshultz SE: Dilated cardiomyopathy in HIV-infected patients. N Engl J Med 1998, 339:1153–1155.PubMedCrossRefGoogle Scholar
  4. 4.
    Felker GM, Thompson RE, Hare JM, et al.: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077–1084.PubMedCrossRefGoogle Scholar
  5. 5.
    Lipshultz SE, Easley KA, Orav EJ, et al.: Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 1998, 97:1246–1256.PubMedGoogle Scholar
  6. 6.
    Lipshultz SE, Easley KA, Orav EJ, et al.: Cardiac dysfunction and mortality in HIV-infected children: The Prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 2000, 102:1542–1548.PubMedGoogle Scholar
  7. 7.
    Starc TJ, Lipshultz SE, Easley KA, et al.: Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: the prospective P2C2 HIV study. J Pediatr 2002, 141:327–334.PubMedCrossRefGoogle Scholar
  8. 8.
    Fisher SD, Lipshultz SE: Epidemiology of cardiovascular involvement in HIV disease and AIDS. Ann NY Acad Sci 2001, 946:13–22.PubMedCrossRefGoogle Scholar
  9. 9.
    Fisher SD, Lipshultz SE: Cardiac disease. In AIDS Therapy, edn 2. Edited by Dolin R, Masur H, Saag MS. Philadelphia: Churchill-Livingstone; 2002:814–826.Google Scholar
  10. 10.
    Kasten-Sportes C, Weinstein C: Molecular mechanisms of HIV cardiovascular disease. In Cardiology in AIDS. Edited by Lipshultz SE. New York: Chapman and Hall; 1998:265–282.Google Scholar
  11. 11.
    Currie PF, Goldman JH, Caforio AL, et al.: Cardiac autoimmunity in HIV related heart muscle disease. Heart 1998, 79:599–604.PubMedGoogle Scholar
  12. 12.
    Currie PF, Boon NA: Immunopathogenesis of HIV-related heart muscle disease: current perspectives. AIDS 2003, 17:S21-S28.PubMedCrossRefGoogle Scholar
  13. 13.
    Luginbuhl LM, Orav EJ, McIntosh K, Lipshultz SE: Cardiac morbidity and related mortality in children with HIV infection. JAMA 1993, 269:2869–2875.PubMedCrossRefGoogle Scholar
  14. 14.
    Al-Attar I, Orav EJ, Exil V, et al.: Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. J Am Coll Cardiol 2003, 41:1598–1605. This is a current longitudinal study of risk factors for cardiovascular disease in HIV.PubMedCrossRefGoogle Scholar
  15. 15.
    Lipshultz SE, Orav EJ, Sanders SP, Colan SD: Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation 1995, 92:2220–2225.PubMedGoogle Scholar
  16. 16.
    Lipshultz SE, Fisher SD, Lai WW, Miller TL: Cardiovascular monitoring and therapy for HIV-infected patients. Ann NY Acad Sci 2001, 946:236–273.PubMedCrossRefGoogle Scholar
  17. 17.
    Fisher SD, Bowles NE, Towbin JA, Lipshultz SE: Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes. AIDS 2003, 17:S29-S35.PubMedGoogle Scholar
  18. 18.
    Lipshultz SE, Fisher SD, Lai WW, Miller TL: Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 2003, 17:S96-S122. This is a comprehensive review of monitoring and therapy for HIVrelated cardiotoxicity and a great reference tool for clinicians.PubMedGoogle Scholar
  19. 19.
    Heidenreich PA, Eisenberg MJ, Kee LL, et al.: Pericardial effusion in AIDS. Incidence and survival. Circulation 1995, 92:3229–3234.PubMedGoogle Scholar
  20. 20.
    Rerkpattanapipat P, Wongpraparut N, Jacobs LE, Kotler MN: Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 2000, 160:602–608. This is a very thorough review of recent data in the field of AIDSrelated cardiotoxicity.PubMedCrossRefGoogle Scholar
  21. 21.
    Yunis NA, Stone VE: Cardiac manifestations of HIV/AIDS: a review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:145–154.PubMedGoogle Scholar
  22. 22.
    Bruno F, Sacchi P, Filice G: Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: impact of highly active antiretroviral therapy. AIDS 2003, 17:S83-S87.PubMedGoogle Scholar
  23. 23.
    Bestetti RB, Figueiredo JF, Da Costa JC: Salmonella tricuspid endocarditis in an intravenous drug abuser with human immunodeficiency virus infection. Int J Cardiol 1991, 30:361–362.PubMedCrossRefGoogle Scholar
  24. 24.
    Daniel WG, Mugge A, Martin RP, et al.: Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl J Med 1991, 324:795–800.PubMedCrossRefGoogle Scholar
  25. 25.
    Mesa RA, Edell ES, Dunn WF, Edwards WD: Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998, 73:37–45.PubMedGoogle Scholar
  26. 26.
    Aguilar RV, Farber HW: Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000, 162:1846–1850.PubMedGoogle Scholar
  27. 27.
    Jenson HB, Pollock BH: Cardiac cancers in HIV-infected patients. In Cardiology in AIDS. Edited by Lipshultz SE. New York: Chapman and Hall; 1998:255–263.Google Scholar
  28. 28.
    Chu WW, Sosman JM, Stein JH: Clinical cardiac manifestations of HIV infection: a review of current literature. WMJ 2002, 101:40–45. This is a concise and up-to-date informative review of HIV-related cardiotoxicity describing important, rarely cited data.Google Scholar
  29. 29.
    Duong M, Dubois C, Buisson M, et al.: Non-hodgkin’s lymphoma of the heart in patients infected with human immunodeficiency virus. Clin Cardiol 1997, 20:497–502.PubMedCrossRefGoogle Scholar
  30. 30.
    Dal Maso L, Serraino D, Franceschi S: Epidemiology of HIVassociated malignancies. Cancer Treat Res 2001, 104:1–18.Google Scholar
  31. 31.
    Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ: Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 1997, 20:2810–2816.PubMedCrossRefGoogle Scholar
  32. 32.
    Villa A, Foresti V, Confalonieri F: Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin Auton Res 1995, 5:48–52.PubMedCrossRefGoogle Scholar
  33. 33.
    Neild PJ, Amadi A, Ponikowski P, et al.: Cardiac autonomic dysfunction in AIDS is not secondary to heart failure. Int J Cardiol 2000, 74:133–137.PubMedCrossRefGoogle Scholar
  34. 34.
    Becker K, Gorlach I, Frieling T, Haussinger D: Characterization and natural course of cardiac autonomic nervous dysfunction in HIV-infected patients. AIDS 1997, 11:751–757.PubMedCrossRefGoogle Scholar
  35. 35.
    Wong JCL, Med M, Lipshultz SE: Cardiovascular complications of pharmacotherapeutic agents (excluding the antiretrovirals) in HIV-infected patients. In Cardiology in AIDS. Edited by Lipshultz SE. New York: Chapman and Hall; 1998:331–343.Google Scholar
  36. 36.
    Fantoni M, Autore C, Del Borgo C: Drugs and cardiotoxicity in HIV and AIDS. Ann NY Acad Sci 2001, 946:179–199.PubMedCrossRefGoogle Scholar
  37. 37.
    Stein KM, Haronian H, Mensah GA, et al.: Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am J Cardiol 1990, 66:888–889.PubMedCrossRefGoogle Scholar
  38. 38.
    Wharton JM, Demopulos PA, Goldschlager N: Torsade de pointes during administration of pentamidine isethionate. Am J Med 1987, 83:571–576.PubMedCrossRefGoogle Scholar
  39. 39.
    Cardoso JS, Mota-Miranda A, Conde C, et al.: Inhalatory pentamidine therapy and the duration of the QT interval in HIVinfected patients. Int J Cardiol 1997, 59:285–289.PubMedCrossRefGoogle Scholar
  40. 40.
    Lipshultz SE, Chanock S, Sanders SP, et al.: Cardiovascular manifestations of human immunodeficiency virus infection in infants and children. Am J Cardiol 1989, 63:1489–1497.PubMedCrossRefGoogle Scholar
  41. 41.
    Lipshultz SE, Easley KA, Orav EJ, et al.: Cardiovascular status of infants and children of women infected with HIV-1 (P2C2 HIV): a cohort study. Lancet 2002, 360:368–373. This details long-term follow-up of a prospective birth cohort with HIV infection and an appropriate control population and reviews cardiac involvement.PubMedCrossRefGoogle Scholar
  42. 42.
    Fisher SD, Easley KA, Orav EJ, et al.: Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: fullterm results from the prospective P2C2 HIV multicenter study. J Am Coll Cardiol 2003, In press.Google Scholar
  43. 43.
    Sullivan JL, Luzuriaga K: The changing face of pediatric HIV-1 infection. N Engl J Med 2001, 345:1568–1569.PubMedCrossRefGoogle Scholar
  44. 44.
    Pugliese A, Isnardi D, Saini A, et al.: Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000, 40:282–284.PubMedCrossRefGoogle Scholar
  45. 45.
    Dube MP, Sprecher D, Henry WK, et al.: Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000, 31:1216–1224.PubMedCrossRefGoogle Scholar
  46. 46.
    Rickerts V, Brodt H, Staszewski S, Stille W: Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000, 5:329–333.PubMedGoogle Scholar
  47. 47.
    Holmberg SD, Moorman AC, Williamson JM, et al.: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002, 360:1747–1748.PubMedCrossRefGoogle Scholar
  48. 48.
    Harmon WG, Dadlani GH, Fisher SD, Lipshultz SE: Myocardial and pericardial disease in HIV. Curr Treat Options Cardiovasc Med 2002, 4:497–509.PubMedGoogle Scholar
  49. 49.
    Miller TL: Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy. AIDS 2003, 17:S130-S140.PubMedCrossRefGoogle Scholar
  50. 50.
    Danner SA, Carr A, Leonard JM, et al.: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995, 333:1528–1533.PubMedCrossRefGoogle Scholar
  51. 51.
    Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002, 31:257–275.PubMedGoogle Scholar
  52. 52.
    Hoffmann C, Jaeger H: Cardiology and AIDS--HAART and the consequences. Ann NY Acad Sci 2001, 946:130–144.PubMedCrossRefGoogle Scholar
  53. 53.
    Scevola D, Di Matteo A, Lanzarini P, et al.: Effects of exercise and strength training on cardiovascular status in HIVinfected patients receiving highly active antiretroviral therapy. AIDS 2003, 17:S123-S129.PubMedCrossRefGoogle Scholar
  54. 54.
    Stein JH, Klein MA, Bellehumeur JL, et al.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104:257–262.PubMedGoogle Scholar
  55. 55.
    Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and prevention and the American Heart Association. Circulation 2003, 107:499–511.PubMedCrossRefGoogle Scholar
  56. 56.
    Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385–394.PubMedCrossRefGoogle Scholar
  57. 57.
    Hsue P, Lo J, Franklin A, et al.: Increased atherosclerotic progression in patients with HIV: the role of traditional and immunologic risk factors [abstract]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 10–14, 2003.Google Scholar
  58. 58.
    Vittecoq D, Escaut L, Chironi G, et al.: Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 2003, 17:S70-S76.PubMedGoogle Scholar
  59. 59.
    Mooser V: Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? AIDS 2003, 17:S65-S69.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Karolina M. Zareba
  • Steven E. Lipshultz
    • 1
  1. 1.Department of PediatricsUniversity of MiamiMiamiUSA

Personalised recommendations